poisar

Stocks · News reference

Wedbush Initiates Coverage On Eupraxia Pharmaceuticals with Outperform Rating, Announces Price Target of $17

BenzingaBenzinga Newsdesk

Wedbush analyst Martin Fan initiates coverage on Eupraxia Pharmaceuticals (NASDAQ:EPRX) with a Outperform rating and announces Price Target of $17.

Reference Details

Connected Markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

Source
benzinga
Observed
Checked
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading

  1. BenzingaBenzinga Newsdesk

    Eupraxia Pharmaceuticals Q2 EPS $(0.23), Inline

    Eupraxia Pharmaceuticals (NASDAQ:EPRX) reported quarterly losses of $(0.23) per share which met the analyst consensus estimate. This is a 11.54 percent increase over losses of $(0.26) per share from the same period last